BioCentury
ARTICLE | Politics, Policy & Law

Jockeying for market exclusivity; RAC begins to resurface

July 21, 1997 7:00 AM UTC

Washington

WASHINGTON - Biotechnology and research-based pharmaceutical companies have reacted favorably to FDA's proposal to extend the marketing exclusivity period for newly approved products based on a single enantiomer of a previously approved racemate to five years from the current three-year period...